Clinical characteristics associated with BRAF, NRAS and KIT mutations in Japanese melanoma patients
Kaori Sakaizawa(Shinshu University), Hisashi Uhara(Sapporo Medical University), Shigeto Matsushita(National Hospital Organization), Naohito Hatta(Toyama Prefectural Central Hospital), Yasuhiro Fujisawa(University of Tsukuba), Takamichi Ito(Kyushu University), Ryuhei Okuyama(Shinshu University), Jiro Uehara(Asahikawa Medical University), Aya Uchiyama(Shinshu University), Atsuko Ashida(Ōtani University), Tatsuya Takenouchi(Niigata Cancer Center Hospital), Dai Ogata(Unknown), Kazuyasu Fujii(Kindai University Hospital), Naoya Yamazaki(Tokyo National Hospital), Yoshitsugu Shibayama(Fukuoka University), Satoshi Fukushima(Niigata Cancer Center Hospital)
Cited by 120
Related Papers
Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2018|1k
Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments
|Cancer Cell|2022|828
The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies
|Nature Immunology|2020|810
Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial
|The Lancet Oncology|2018|586
Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity
|Cancer Cell|2022|338